Immunization, Hib3 in Burkina Faso
Burkina Faso: Immunization, Hib3 was 91.0% in 2024. ▬ Flat
Immunization, Hib3 in Burkina Faso, 2006–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
The most recent figure for immunization, hib3 in Burkina Faso is 91.0%, measured in 2024.
That represents a change of unchanged over ten years.
Over the whole period, immunization, hib3 in Burkina Faso peaked at 93.0% in 2008 and was at its lowest, 76.0%, in 2006.
That places Burkina Faso 90th out of 191 countries with data for 2024, putting it in the middle of the range.
Immunization, Hib3 in Burkina Faso, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 2006 | 76.0% | — |
| 2007 | 89.0% | +17.1% |
| 2008 | 93.0% | +4.5% |
| 2009 | 92.0% | -1.1% |
| 2010 | 91.0% | -1.1% |
| 2011 | 91.0% | +0.0% |
| 2012 | 90.0% | -1.1% |
| 2013 | 88.0% | -2.2% |
| 2014 | 91.0% | +3.4% |
| 2015 | 91.0% | +0.0% |
| 2016 | 91.0% | +0.0% |
| 2017 | 91.0% | +0.0% |
| 2018 | 91.0% | +0.0% |
| 2019 | 91.0% | +0.0% |
| 2020 | 91.0% | +0.0% |
| 2021 | 91.0% | +0.0% |
| 2022 | 91.0% | +0.0% |
| 2023 | 91.0% | +0.0% |
| 2024 | 91.0% | +0.0% |
Burkina Faso compared with similar countries
- Burkina Faso's 91.0% is above the median for low income countries, which is 73.0%, 1.2× the median. (25 countries reporting)
- Burkina Faso's 91.0% is above the median for Sub-Saharan Africa, which is 82.5%, 1.1× the median. (48 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 87.5% | 76.0% | 93.0% | 4 |
| 2010s | 90.6% | 88.0% | 91.0% | 10 |
| 2020s | 91.0% | 91.0% | 91.0% | 5 |
Countries ranked near Burkina Faso
More health data for Burkina Faso
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.8925 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,142 deaths per 1,000 people (2090)
- Number of infants who die before age 1 13,085 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 4 (2025)
- Population ages 00-04, female, annual growth rate 0.8681 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0693 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.7133 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
Frequently asked questions
- What is immunization, hib3 in Burkina Faso?
- Immunization, hib3 in Burkina Faso was 91.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Burkina Faso?
- The highest recorded value was 93.0% in 2008.
- What is the lowest immunization, hib3 recorded in Burkina Faso?
- The lowest recorded value was 76.0% in 2006.
- How does Burkina Faso rank for immunization, hib3?
- Burkina Faso ranks 90th out of 191 countries with data for 2024.
- Is immunization, hib3 rising or falling in Burkina Faso?
- Over the last ten years it is unchanged. The long-run trend across the full record is flat.
- Where does this Burkina Faso data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 19 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.